Upstate Active Clinical Trials

Study Title:

CALGB 80802: Phase III Randomized Study of Sorafenib (IND 69896, NSC 724772) Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)

What is the purpose of the study?

This randomized phase III trial is studying sorafenib tosylate and doxorubicin hydrochloride to see how well they work compared with sorafenib tosylate alone in treating patients with locally advanced or metastatic liver cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving sorafenib tosylate together with doxorubicin hydrochloride is more effective than sorafenib tosylate alone in treating liver cancer.

Upstate Institutional Review Board (IRB) Number:

240642

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Jonathan Wright, MD

ClinicalTrials.Gov ID:

NCT01015833

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Wendy S Barry
Phone: 315-464-8271
Email: barryw@upstate.edu

Return to Previous Page || Search Again